Gent for Pharyngeal Gonorrhea (GC)
|ClinicalTrials.gov Identifier: NCT03632109|
Recruitment Status : Terminated (Efficacy)
First Posted : August 15, 2018
Last Update Posted : April 9, 2019
The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR) Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats. Since the advent of antibiotics in the 1930s, NG has developed resistance to every first-line antibiotic. Parenteral third-generation cephalosporins are now the only class of drug with consistent efficacy against NG. New therapies are urgently needed. Although some novel antimicrobials are under development, reevaluating older drugs is another option for quickly identifying additional treatments for gonorrhea. We propose a demonstration study to test a single dose of gentamicin for the treatment of pharyngeal gonorrhea. We chose to focus on pharyngeal gonorrhea because these infections are common, play an important role in fostering gonococcal resistance, and are harder to eradicate than genital infections. Although gentamicin is 91% efficacious for genital NG, its efficacy at the pharynx may be less since streptomycin, another aminoglycoside previously used to treat gonorrhea, was not effective for pharyngeal NG. It is unknown if streptomycin's poor efficacy is indicative of limitations of aminoglycosides as a class. We plan to enroll 60 men who have sex with men in a demonstration study to be conducted at the Seattle & King County STD Clinic to test the efficacy of 360 mg of gentamicin given intramuscularly for pharyngeal gonorrhea. Secondary objectives include determining the ideal pharmacodynamic criterion (comparing in vitro minimal inhibitory concentrations (MIC) of NG to peak gentamicin serum levels), estimating resistance induction among treatment failures, and assessing the tolerability of 360 mg of IM gentamicin.
The proposed study aims to evaluate the efficacy of a single intramuscular (IM) dose of gentamicin in the treatment of pharyngeal gonorrhea. Secondary objectives include documenting the efficacy stratified by minimal inhibitory concentration (MIC) compared with the gentamicin peak level in order to estimate a pharmacodynamic criterion. We will also attempt to determine whether gentamicin monotherapy induces antimicrobial resistance among treatment failures. Lastly, we will evaluate the tolerability of 360 mg of IM gentamicin, stratified by subject weight (i.e. weight based dosing). The specific aims are:
- Determine the proportion of persons whose pharyngeal gonococcal infections are cured with a single dose of 360mg gentamicin intramuscularly alone.
- Evaluate the renal safety and tolerability of 360mg IM of gentamicin.
- Document mean peak gentamicin levels following 360mg IM of gentamicin stratified by weight.
- Estimate the best pharmacodynamics criterion (i.e. peak/MIC ratio) for pharyngeal gonorrhea treated with gentamicin using individual and mean peak gentamicin levels and NG isolate MIC.
- Among treatment failures, conduct exploratory analyses comparing pre- and post-treatment MIC for evidence of induced resistance.
|Condition or disease||Intervention/treatment||Phase|
|Pharyngeal Gonococcal Infection||Drug: gentamicin 360mg IM||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Gentamicin for Pharyngeal Gonorrhea - A Demonstration Study|
|Actual Study Start Date :||September 17, 2018|
|Actual Primary Completion Date :||March 12, 2019|
|Actual Study Completion Date :||March 12, 2019|
Experimental: Single Arm
Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
Drug: gentamicin 360mg IM
360mg IM of gentamicin
- Cure Rate defined as the proportion of persons with pharyngeal gonorrhea treated with gentamicin 360mg IM who have a negative culture 4-7 days following treatment [ Time Frame: 4-7 days (+/- 1 day) after treatment ]Negative Pharyngeal Culture
- Renal Safety as measured by a change in serum creatinine from before treatment to 4-7 days following treatment [ Time Frame: 4-7 days (+/- 1 day) after treatment ]A >=40% increase in serum Creatinine
- Tolerability of gentamicin 360mg IM x 1: Adverse events [ Time Frame: 4-7 days (+/- 1 day) after treatment ]Adverse events as described by subjects' responses to standardized side effect questionnaire at the TOC visit
- Peak Gentamicin levels [ Time Frame: at 30, 45, or 60 minutes post dose ]serum gentamicin concentration
- Gentamicin minimal inhibitory concentration (MIC) [ Time Frame: baseline/enrollment visit ]laboratory defined MIC of infecting strain of N. gonorrhoeae at enrollment visit determined by agar dilution
- Exploratory study: look for evidence of induced resistance [ Time Frame: 4-7 days (+/- 1 day) after treatment ]Among treatment failures, compare pre-treatment and post-treatment minimal inhibitory concentrations (MIC)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03632109
|United States, Washington|
|Public Health -- Seattle & King County STD Clinic|
|Seattle, Washington, United States, 98104|
|Principal Investigator:||Lindley A Barbee, MD, MPH||University of Washington|